Johnson & Johnson is aiming for the combination of Rybrevant (amivantamab-vmjw) and Lazcluze (lazertinib) to become the preferred treatment for patients with first-line locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletions (ex19del) or L858R substitution mutations after beating the standard of care.
J&J Rybrevant/Lazcluze Combo Shows Big Survival Advantage In MARIPOSA Study
Topline Phase III results in EGFR exon 19 deletion/L858R substitution mutation NSCLC indicate more than a year in overall survival improvement over Tagrisso, the current standard of care.
